Clinical and Biochemical Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on the Prognosis of Preterm Infants with Early Onset Neonatal Sepsis
| Author | Reza Saeidi | en |
| Author | Hossein Akhavan | en |
| Author | Jalil Tavakkolafshari | en |
| Author | Abbas Shapouri-Moghaddam | en |
| Orcid | Jalil Tavakkolafshari [0000-0003-0146-5021] | en |
| Issued Date | 2019-01-31 | en |
| Abstract | Background: A double-blind, placebo-controlled randomized trial was designed to investigate the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on the prognosis of preterm infants with early onset neonatal sepsis (EONS). Methods: Fifty preterm infants were selected from the neonatal intensive care unit (NICU) of Qaem Hospital, Mashhad, Iran in 2011. They were randomized to rhG-CSF (intervention group, n = 25) or identical placebo (control group, n = 25) for 3 days. The following blood parameters were measured: White blood cells count (WBC), absolute neutrophil count (ANC), serum level of high-sensitivity C-reactive protein (hs-CRP), and the ratio of immature to total neutrophils. In addition, the mortality rate, adverse effects, and duration of hospital stay were evaluated as clinical parameters. Results: At baseline, both groups were not significantly different (P > 0.05) except for the hs-CRP level (P = 0.024) and hypoglycemia (P = 0.001). Compared with the controls, significant improvements were only observed in WBC (P = 0.001) and ANC (P = 0.010) of the intervention group. The mean difference in the WBC, ANC, hs-CRP level, and the ratio of immature to total neutrophils between the baseline and 3-day post-treatment values was higher in the controls than the intervention group. More than 90% of the patients exposed to either rhG-CSF or placebo hospitalized for over 72 hours and no significant difference was found between them (P = 0.946). In each group, a decease was recorded (4.0%) during the hospitalization. Conclusions: The rhG-CSF administration could effectively improve WBC and ANC. No significant changes were observed in mortality rate, adverse effects, and hospital stay after the treatment. | en |
| DOI | https://doi.org/10.5812/pedinfect.67807 | en |
| Keyword | Recombinant Human Granulocyte Colony Stimulating Factor | en |
| Keyword | Early Onset Neonatal Sepsis | en |
| Keyword | Preterm Infants | en |
| Keyword | Randomized Controlled Trial | en |
| Publisher | Brieflands | en |
| Title | Clinical and Biochemical Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on the Prognosis of Preterm Infants with Early Onset Neonatal Sepsis | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- apid-7-1-67807.pdf
- Size:
- 140.38 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF